Alzinova AB is a privately held Swedish biotechnology enterprise engaged in drug discovery research for Alzheimer’s disease. A platform technology based on the AβCC™ peptides provides the company with long-term R&D capabilities. This technology enables Alzinova to explore novel therapeutic strategies and develop research tools that enhance productivity within Alzheimer's disease research.Read more »
Non-fibrillogenic mimics of endogenous toxic amyloid-β aggregates ('oligomers') are developed by Alzinova as vaccines with high efficacy, and non-toxic mimetic amyloid-β as replacement therapy. The unique properties of the AβCC™ peptide platform technology has also enabled the development of a monoclonal antibody with 100% specificity for the disease-driving oligomers.
Alzinova is featured in a co-distributed supplement to the leading Swedish business magazine “Dagens Industri”… Read more »
The Alzheimer’s Association 2013 Alzheimer’s Disease Facts and Figures is a statistical resource for US… Read more »
In an effort to speed the development of Alzheimer’s disease therapeutics, the FDA has now… Read more »